In addition, the PARP inhibitor olaparib is used in combination with ferroptosis inducers to enhance the sensitivity of BRCAproficient ovarian cancer cells to olaparib by inhibiting solute carrier family 7 member 11 (SLC7A11)‐mediated GSH synthesis.15 The gene discussed is SLC7A11; the disease is ovarian carcinoma.